Pyxis Oncology Net Cash Flow 2021-2025 | PYXS

Pyxis Oncology net cash flow from 2021 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

Pyxis Oncology Net Cash Flow 2021-2025 | PYXS

Pyxis Oncology net cash flow from 2021 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$76.6B
Zoetis (ZTS)$69B
Takeda Pharmaceutical (TAK)$46.7B
Daiichi Sankyo, - (DSNKY)$41.7B
BeOne Medicines - (ONC)$27.4B
Sandoz Group AG (SDZNY)$24.6B
Summit Therapeutics (SMMT)$18.6B
Merck (MKKGY)$17.2B
Shionogi (SGIOY)$14.2B
United Therapeutics (UTHR)$13.3B
Neurocrine Biosciences (NBIX)$13.2B
Orion OYJ (ORINY)$11B
IPSEN (IPSEY)$10.3B
Stevanato Group S.p.A (STVN)$7.6B
Corcept Therapeutics (CORT)$7.6B
Madrigal Pharmaceuticals (MDGL)$7B
Grifols, S.A (GRFS)$6.7B
Ionis Pharmaceuticals (IONS)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.1B
Soleno Therapeutics (SLNO)$4.1B
Crinetics Pharmaceuticals (CRNX)$3B
Hypermarcas (HYPMY)$3B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.4B
Centessa Pharmaceuticals (CNTA)$1.9B
BioCryst Pharmaceuticals (BCRX)$1.8B
Ocular Therapeutix (OCUL)$1.8B
ARS Pharmaceuticals (SPRY)$1.7B